{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T06:31:10Z","timestamp":1778567470289,"version":"3.51.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,10,29]],"date-time":"2014-10-29T00:00:00Z","timestamp":1414540800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1007\/s10157-014-1047-1","type":"journal-article","created":{"date-parts":[[2014,10,28]],"date-time":"2014-10-28T16:58:07Z","timestamp":1414515487000},"page":"746-752","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Safety study of somatostatin analogue octreotide for autosomal dominant polycystic kidney disease in Japan"],"prefix":"10.1007","volume":"19","author":[{"given":"Eiji","family":"Higashihara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kikuo","family":"Nutahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takatsugu","family":"Okegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiro","family":"Tanbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isao","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Nitatori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuninori","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,10,29]]},"reference":[{"key":"1047_CR1","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/ki.1992.195","volume":"41","author":"PA Gabow","year":"1992","unstructured":"Gabow PA, Johnson AM, Kaehny WD, Kimberling WL, Lezotte DC, Duley IT, Jones RH. Factors affecting the prognosis of renal disease in autosomal dominant polycystic kidney disease. Kidney Int. 1992;41:1311\u20139.","journal-title":"Kidney Int"},{"key":"1047_CR2","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1159\/000045214","volume":"80","author":"E Higashihara","year":"1998","unstructured":"Higashihara E, Nutahara K, Kojima M, Tamakoshi A, Ohno Y, Sakai H, Kurokawa K. Prevalence and renal prognosis of diagnosed autosomal dominant polycystic kidney disease in Japan. Nephron. 1998;80:421\u20137.","journal-title":"Nephron"},{"key":"1047_CR3","doi-asserted-by":"crossref","first-page":"710","DOI":"10.2215\/CJN.01581105","volume":"1","author":"E Dicks","year":"2006","unstructured":"Dicks E, Ravani P, Langman D, Davidson WS, Pei Y, Parfrey PS. Incident renal events and risk factors in autosomal dominant polycystic kidney disease: a population and family-based cohort followed for 22\u00a0years. Clin J Am Soc Nephrol. 2006;1:710\u20137.","journal-title":"Clin J Am Soc Nephrol."},{"key":"1047_CR4","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/0002-9343(80)90266-1","volume":"68","author":"J Milutinovic","year":"1980","unstructured":"Milutinovic J, Fialkow PJ, Rudd TG, Agodoa LY, Phillips LA, Bryant JI. Liver cysts in patients with autosomal dominant polycystic kidney disease. Am J Med. 1980;68:741\u20134.","journal-title":"Am J Med"},{"key":"1047_CR5","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0022-5347(17)37228-2","volume":"147","author":"E Higashihara","year":"1992","unstructured":"Higashihara E, Aso Y, Shimazaki J, Ito H, Koiso K, Sakai O. Clinical aspects of polycystic kidney disease. J Urol. 1992;147:329\u201332.","journal-title":"J Urol"},{"key":"1047_CR6","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1097\/01.ASN.0000029587.47950.25","volume":"13","author":"BK Yoder","year":"2002","unstructured":"Yoder BK, Hou X, Guay-Woodford LM. The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and Cystin, are co-localized in renal cilia. J Am Soc Nephrol. 2002;13:2508\u201316.","journal-title":"J Am Soc Nephrol"},{"key":"1047_CR7","doi-asserted-by":"crossref","first-page":"R378","DOI":"10.1016\/S0960-9822(02)00877-1","volume":"12","author":"GJ Pazour","year":"2002","unstructured":"Pazour GJ, San Agustin JT, Follit JA, Rosenbaum JL, Witman GB. Polycystin-2 localizes to kidney cilia and the ciliary level is elevated in orpk mice with polycystic kidney disease. Curr Biol. 2002;12:R378\u201380.","journal-title":"Curr Biol"},{"key":"1047_CR8","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.gastro.2003.09.001","volume":"125","author":"TV Masyuk","year":"2003","unstructured":"Masyuk TV, Huang BQ, Ward CJ, Masyuk AI, Yuan D, Splinter PL, Punyashthiti R, Ritman EL, Torres VE, Harris PC, LaRusso NF. Defects in cholangiocyte fibrocystin expression and ciliary structure in the PCK rat. Gastroenterology. 2003;125:1303\u201310.","journal-title":"Gastroenterology"},{"key":"1047_CR9","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1053\/j.gastro.2006.07.003","volume":"131","author":"AI Masyuk","year":"2006","unstructured":"Masyuk AI, Masyuk TV, Splinter PL, Huang BQ, Stroope AJ, LaRusso NF. Cholangiocyte cilia detect changes in luminal fluid flow and transmit them into intracellular Ca2+ and cAMP signaling. Gastroenterology. 2006;131:911\u201320.","journal-title":"Gastroenterology"},{"key":"1047_CR10","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00232-001-0075-4","volume":"184","author":"HA Praetorius","year":"2001","unstructured":"Praetorius HA, Spring KR. Bending the MDCK cell primary cilium increases intracellular calcium. J Membr Biol. 2001;184:71\u20139.","journal-title":"J Membr Biol"},{"key":"1047_CR11","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/00041552-200309000-00006","volume":"12","author":"HA Praetorius","year":"2003","unstructured":"Praetorius HA, Spring KR. The renal cell primary cilium function as a flow sensor. Curr Opin Nephrol Hypertens. 2003;12:517\u201320.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"1047_CR12","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0272-6386(97)90496-0","volume":"30","author":"T Yamaguchi","year":"1997","unstructured":"Yamaguchi T, Nagao S, Kasahara M, Takahashi H, Grantham JJ. Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease. Am J Kidney Dis. 1997;30:703\u20139.","journal-title":"Am J Kidney Dis"},{"key":"1047_CR13","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/hep.22636","volume":"49","author":"JM Banales","year":"2009","unstructured":"Banales JM, Masyuk TV, Gradilone SA, Masyuk AI, Medina JF, LaRusso NF. The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD). Hepatology. 2009;49:160\u201374.","journal-title":"Hepatology"},{"key":"1047_CR14","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","volume":"369","author":"VE Torres","year":"2007","unstructured":"Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007;369:1287\u2013301.","journal-title":"Lancet"},{"key":"1047_CR15","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1046\/j.1523-1755.2000.00991.x","volume":"57","author":"T Yamaguchi","year":"2000","unstructured":"Yamaguchi T, Pelling JC, Ramaswamy NT, Eppl.er JW, Wallace DP, Nagao S, Rome LA, Sullivan LP, Grantham JJ. cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int. 2000;57:1460\u201371.","journal-title":"Kidney Int"},{"key":"1047_CR16","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1681\/ASN.V1171179","volume":"11","author":"K Hanaoka","year":"2000","unstructured":"Hanaoka K, Guggino WB. cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells. J Am Soc Nephrol. 2000;11:1179\u201387.","journal-title":"J Am Soc Nephrol"},{"key":"1047_CR17","doi-asserted-by":"crossref","first-page":"F1005","DOI":"10.1152\/ajprenal.00243.2011","volume":"301","author":"GA Reif","year":"2011","unstructured":"Reif GA, Yamaguchi T, Nivens E, Fujiki H, Pinto CS, Wallace DP. Tolvaptan inhibits ERK-dependent cell proliferation, Cl\u2212 secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin. Am J Physiol Renal Physiol. 2011;301:F1005\u201313.","journal-title":"Am J Physiol Renal Physiol."},{"key":"1047_CR18","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/nm935","volume":"9","author":"VH Gattone 2nd","year":"2003","unstructured":"Gattone VH 2nd, Wang X, Harris PC, Torres VE. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med. 2003;9:1323\u20136.","journal-title":"Nat Med"},{"key":"1047_CR19","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nm1004","volume":"10","author":"VE Torres","year":"2004","unstructured":"Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH 2nd. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med. 2004;10:363\u20134.","journal-title":"Nat Med"},{"key":"1047_CR20","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.2215\/CJN.03530411","volume":"6","author":"E Higashihara","year":"2011","unstructured":"Higashihara E, Torres VE, Chapman AB, Grantham JJ, Bae K, Watnick TJ, Horie S, Nutahara K, Ouyang J, Krasa HB, Czerwiec FS. Tolvaptan in autosomal dominant polycystic kidney disease: three years\u2019 experience. Clin J Am Soc Nephrol. 2011;6:2499\u2013507.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1047_CR21","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J. Czerwiec FS; TEMPO 3:4 Trial Investigators. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367:2407\u201318.","journal-title":"N Engl J Med"},{"key":"1047_CR22","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1053\/j.gastro.2006.12.039","volume":"132","author":"TV Masyuk","year":"2007","unstructured":"Masyuk TV, Masyuk AI, Torres VE, Harris PC, Larusso NF. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3\u2032,5\u2032-cyclic monophosphate. Gastroenterology. 2007;132:1104\u201316.","journal-title":"Gastroenterology"},{"key":"1047_CR23","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/0014-5793(86)81180-2","volume":"198","author":"G Friedlander","year":"1986","unstructured":"Friedlander G, Amiel C. Somatostatin and alpha 2-adrenergic agonists selectively inhibit vasopressin-induced cyclic AMP accumulation in MDCK cells. FEBS Lett. 1986;198:38\u201342.","journal-title":"FEBS Lett"},{"key":"1047_CR24","first-page":"8","volume":"7","author":"SN Winkler","year":"1982","unstructured":"Winkler SN, Torikai S, Levine BS, Kurokawa K. Effect of somatostatin on vasopressin-induced antidiuresis and renal cyclic AMP of rats. Miner Electrolyte Metab. 1982;7:8\u201314.","journal-title":"Miner Electrolyte Metab"},{"key":"1047_CR25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0928-4257(00)00206-0","volume":"94","author":"G Ferjoux","year":"2000","unstructured":"Ferjoux G, Bousquet C, Cordelier P, Benali N, Lopez F, Rochaix P, Buscail L, Susini C. Signal transduction of somatostatin receptors negatively controlling cell proliferation. J Physiol Paris. 2000;94:205\u201310.","journal-title":"J Physiol Paris."},{"key":"1047_CR26","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1523-1755.2005.00395.x","volume":"68","author":"P Ruggenenti","year":"2005","unstructured":"Ruggenenti P, Remuzzi A, Ondei P, Fasolini G, Antiga L, Ene-Iordache B, Remuzzi G, Epstein FH. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int. 2005;68:206\u201316.","journal-title":"Kidney Int"},{"key":"1047_CR27","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1053\/j.gastro.2009.07.052","volume":"137","author":"L Keimpema van","year":"2009","unstructured":"van Keimpema L, Nevens F, Vanslembrouck R, van Oijen MG, Hoffmann AL, Dekker HM, de Man RA, Drenth JP. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2009;137:1661\u20138.","journal-title":"Gastroenterology"},{"key":"1047_CR28","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1681\/ASN.2009121291","volume":"21","author":"MC Hogan","year":"2010","unstructured":"Hogan MC, Masyuk TV, Page LJ, Kubly VJ, Bergstralh EJ, Li X, Kim B, King BF, Glockner J, HolmesIII DR, Rossetti S, Harris PC, LaRusso NF, Torres VE. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol. 2010;21:1052\u201361.","journal-title":"J Am Soc Nephrol"},{"key":"1047_CR29","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0140-6736(13)61407-5","volume":"382","author":"A Caroli","year":"2013","unstructured":"Caroli A, Perico N, Perna A, Antiga L, Brambilla P, Pisani A, Visciano B, Imbriaco M, Messa P, Cerutti R, Dugo M, Cancian L, Buongiorno E, De Pascalis A, Gaspari F, Carrara F, Rubis N, Prandini S, Remuzzi A, Remuzzi G, Ruggenenti P. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. Lancet. 2013;382:1485\u201395.","journal-title":"Lancet"},{"key":"1047_CR30","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1681\/ASN.2008050507","volume":"20","author":"Y Pei","year":"2009","unstructured":"Pei Y, Obaji J, Dupuis A. Paterson AD, Magistroni R, Dicks E, Parfrey P, Cramer B, Coto E, Torra R, San Millan JL, Gibson R, Breuning M, Peters D, Ravine D. Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol. 2009;20:205\u201312.","journal-title":"J Am Soc Nephrol"},{"key":"1047_CR31","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Ymagata K, Tomino Y, Yokoyama H, Hishida A. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392.","journal-title":"Am J Kidney Dis"},{"key":"1047_CR32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10157-013-0834-4","volume":"18","author":"E Higashihara","year":"2014","unstructured":"Higashihara E, Nutahara K, Okegawa T, Shishido T, Tanbo M, Kobayashi K, Nitadori T. Kidney volume and function in autosomal dominant polycystic kidney disease. Clin Exp Nephrol. 2014;18:157\u201365.","journal-title":"Clin Exp Nephrol."},{"key":"1047_CR33","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000256657","volume":"31","author":"B Orskov","year":"2010","unstructured":"Orskov B. Borresen ML, Feldt- Rasmussen B, Ostergaard O, Laursen I, Strandgaard S. Estimating Glomerular filtration rate using the new CKD- EPI equation and other equations in patients with autosomal dominant polycystic kidney disease. Am J Nephrol. 2010;31:53\u20137.","journal-title":"Am J Nephrol"},{"key":"1047_CR34","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1053\/j.ajkd.2012.07.007","volume":"61","author":"M Horio","year":"2013","unstructured":"Horio M, Imai E, Yasuda Y, Watanabe T, Matsuo S. Collaborators Developing the Japanese Equation for Estimated GFR. GFR estimation using standardized serum cystatin C in Japan. Am J Kidney Dis. 2013;61:197\u2013203.","journal-title":"Am J Kidney Dis"},{"key":"1047_CR35","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2215\/CJN.09500911","volume":"7","author":"AB Chapman","year":"2012","unstructured":"Chapman AB, Bost JE, Torres VE, Guay-Woodford L, Bae KT, Landsittel D, Li J, King BF, Martin D, Wetzel LH, Lockhart ME, Harris PC, Moxey-Mims M, Flessner M, Bennett WM, Grantham JJ. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2012;7:479\u201386.","journal-title":"Clin J Am Soc Nephrol."},{"key":"1047_CR36","doi-asserted-by":"crossref","first-page":"783","DOI":"10.2215\/CJN.05380709","volume":"5","author":"A Caroli","year":"2010","unstructured":"Caroli A, Antiga L, Cafaro M, Fasolini G, Remuzzi A, Remuzzi G, Ruggenenti P. Reducing Polycystic Liver Volume in ADPKD: effects of Somatostatin Analogue Octreotide. Clin J Am Soc Nephrol. 2010;5:783\u20139.","journal-title":"Clin J Am Soc Nephrol."},{"key":"1047_CR37","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1365-2036.2011.04923.x","volume":"35","author":"M Chrispijn","year":"2012","unstructured":"Chrispijn M, Nevens F, Gevers TJ, Vanslembrouck R, van Oijen MG, Coudyzer W, Hoffmann AL, Dekker HM, de Man RA, van Keimpema L, Drenth JP. The long-term outcome of patients with polycystic liver disease treated with lanreotide. Aliment Pharmacol Ther. 2012;35:266\u201374.","journal-title":"Aliment Pharmacol Ther"},{"key":"1047_CR38","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1093\/ndt\/gfs152","volume":"27","author":"MC Hogan","year":"2012","unstructured":"Hogan MC, Masyuk TV, Page L, Holmes DR 3rd, Li X, Bergstralh EJ, Irazabal MV, Kim B, King BF, Glockner JF, Larusso NF, Torres VE. Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. Nephrol Dial Transplant. 2012;27:3532\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"1047_CR39","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","volume":"366","author":"A Colao","year":"2012","unstructured":"Colao A, Petersenn S, Newell-Price J. Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BM; Pasireotide B2305 Study Group. A 12-month phase 3 study of pasireotide in Cushing\u2019s disease. N Engl J Med. 2012;366:914\u201324.","journal-title":"N Engl J Med"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-014-1047-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-014-1047-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-014-1047-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T20:16:27Z","timestamp":1650485787000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-014-1047-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,29]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["1047"],"URL":"https:\/\/doi.org\/10.1007\/s10157-014-1047-1","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,29]]}}}